STARR – Study of Atherosclerosis with Ramipril and Rosiglitazone
Principal contacts
Eva Lonn - McMaster University, Hamilton, Ontario, Canada
Hertzel C. Gerstein - McMaster University, Hamilton, Ontario, Canada
Study design
The Study of Atherosclerosis with Ramipril and Rosiglitazone (STARR) is a clinical trial with a 2×2 factorial design based at 32 centres in nine countries and is a substudy of the Diabetes Reduction Assessment with ramipril and rosiglitazone Medications (DREAM) study. The principal aim of the trial was to investigate the effect of Ramipril (15mg/day) or Rosiglitazone (8mg/day) on carotid intima-media thickness progression in pre-diabetic patients. Individuals were eligible for inclusion if they were aged 30 years or older with impaired glucose tolerance and/or impaired fasting glucose. The study was approved by the ethics committees at all participating centres and all participants provided written informed consent.
Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT00140647
Key publications
Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol. 2009 Jun 2;53(22):2028-35